HOME > TOP STORIES
TOP STORIES
-
ACADEMIA Over 150 Clinical Trials of Epigenetic Drugs, Some with Novel Mechanisms of Action, Underway Worldwide
August 31, 2017
-
REGULATORY MHLW to Form Study Group to Address Leftover Vial Drug Issue, Weighs Multi-Dose Vials
August 30, 2017
-
BUSINESS Mitsubishi Tanabe to Create New Business by Fusing LLPs with Digital Technologies
August 30, 2017
-
REGULATORY New Minister Has Hopes for Pharma Industry in Both Medical and Economic Fronts, Wants to Balance Innovation and Cost
August 29, 2017
-
REGULATORY Opdivo’s Gastric Cancer Use, Avelumab and More Up for MHLW Panel Review/Report on Sept. 8
August 28, 2017
-
BUSINESS Spinraza to Hit Japan Market on August 30
August 28, 2017
-
REGULATORY MHLW Seeks 31.4 Trillion Yen in FY2018 Budget, 630 Billion Yen in Natural Rise for Social Security
August 25, 2017
-
REGULATORY Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
-
REGULATORY Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
-
BUSINESS External Activities of Takeda Unit Axcelead to Go Full Throttle This Autumn: President
August 23, 2017
-
TRENDS Japan Generic Market Decelerating, 3 Majors Log Only Slight Uptick in April-June
August 22, 2017
-
REGULATORY MHLW Study Group to Expand Investigation to Clinics to Determine Causes of Improper Promotional Activities
August 22, 2017
-
REGULATORY Clinical Research Law to Apply to Indirectly Funded Programs Too, MHLW to Clarify Procedures: Official
August 21, 2017
-
TRENDS Pharmas’ Rep Number Corrections in Full Force amid Bleak Market Outlook, Silver Lining Seen in “Specialty” Arena
August 18, 2017
-
BUSINESS Harvoni Top-Selling Drug in Japan in FY2016, Opdivo Jumps but Drop Expected for FY2017: Jiho Tally
August 17, 2017
-
ACADEMIA Japan Gastric Cancer Association to Wait for Opdivo Nod before Guidelines Update, Keytruda Won’t Make It This Time
August 16, 2017
-
REGULATORY 11 Firms Get Approval for Irbesartan Generics towards December Listing, including AG; 26 Flock to Crestor
August 16, 2017
-
REGULATORY NIBIOHN to Promote Drug Discovery in Fields with Unmet Needs by Automating Target Discovery Using AI
August 15, 2017
-
INTERVIEW Me Pharma Sees Opportunities in Low-Cost Strategy, Could Carve Out New Biz Models: President
August 14, 2017
-
REGULATORY Calls Growing for Tougher Requirements to Receive Price Maintenance Premium: Chuikyo
August 10, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…